Guilan Sun
Overview
Explore the profile of Guilan Sun including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
58
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang S, Feng M, Fang Y, Lv L, Sun G, Cheng S, et al.
BMC Psychiatry
. 2023 Apr;
23(1):277.
PMID: 37081401
Aim: To analyze the changes of chronotypes in patients with depression before and after treatment, and explore the effects of different chronotypes on antidepressant treatment and the dimensions of common...
2.
Sun G, Dong Z, Li G, Yuan H, Liu J, Yao X, et al.
Adv Biol (Weinh)
. 2023 Mar;
7(7):e2200317.
PMID: 36949542
Poly (acrylic) acid coated Mn3O4 nanoparticles (PAA@Mn O nanoparticles (PMO, 11.02 nm, -28.93 mV)) are synthesized to investigate whether they can help to improve maize drought tolerance and the relevant...
3.
Fang Y, Guo P, Lv L, Feng M, Wang H, Sun G, et al.
Asian J Psychiatr
. 2023 Feb;
82:103484.
PMID: 36736107
No abstract available.
4.
Jing S, Liu W, Yang K, Lin Y, Yao X, Sun G
Clin Transl Sci
. 2022 Dec;
16(3):447-458.
PMID: 36495036
CSPCHA115 is a highly selective and potent antagonist of chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2). This study aimed to evaluate the pharmacokinetics (PKs), safety, and tolerability of single...
5.
Yang J, Lin L, Long Q, Zhang Q, Sun G, Zhou L, et al.
BioDrugs
. 2022 May;
36(3):393-409.
PMID: 35594017
Background: Pertuzumab is a humanized monoclonal antibody for the treatment of breast cancer. HLX11 is a biosimilar of pertuzumab developed by Shanghai Henlius Biotech, Inc. We conducted a bioequivalence study...
6.
Zhang P, Xu B, Gui L, Wang W, Xiu M, Zhang X, et al.
Biomark Res
. 2021 Apr;
9(1):24.
PMID: 33845905
Background: Dalpiciclib (SHR6390) is a novel inhibitor of cyclin-dependent kinase 4/6 which demonstrated promising anti-tumor potency in preclinical models. This first-in-human study was conducted to evaluate the tolerability, pharmacokinetics, safety,...
7.
Shi Y, Wang W, Chen C, Sun G, Zhang J, Chen Y
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
. 2021 Apr;
35(3):264-266.
PMID: 33794615
To learn the hearing level and analyze the effect factors of hearing loss of the ear with normal hearing in patients with single sided deafness, and provide references for the...
8.
Zhang J, Wang W, Wang Y, Chen C, Sun G, Chen Y
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
. 2020 Nov;
34(11):1002-1004.
PMID: 33254319
The study is aimed to evaluate impacts of cochlear implantation on speech perception and quality of life in postlingual deaf adults, and to explore the correlation between speech perception and...
9.
Wang L, Yang L, Zhang J, Xu M, Han Y, Yang Y, et al.
J Mol Neurosci
. 2020 May;
70(9):1445-1450.
PMID: 32468216
Emerging evidence has suggested that patients with ischemic stroke (IS) and/or transient ischemic attack (TIA) are more likely to exhibit myocardial disorders, which can be reflected by transthoracic echocardiography (TTE)....
10.
Sun L, Yang Y, Vertosick E, Jo S, Sun G, Mao J
J Glob Oncol
. 2017 Dec;
3(6):692-700.
PMID: 29244994
Purpose We aimed to quantify Chinese cancer survivors' perceived needs for survivorship care and to evaluate whether these needs could impact their willingness to use traditional Chinese medicine (TCM). Methods...